Login to Your Account



Acorda Files NDA for Fampridine-SR

By Jennifer Boggs


Tuesday, February 3, 2009
Following two successful Phase III studies last year, Acorda Therapeutics Inc. submitted its new drug application as expected for Fampridine-SR, hoping to gain approval of the first drug specifically aimed at improving walking ability in patients with multiple sclerosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription